Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
CRO Sygnature Discovery plans to send 60 UK staffers packing
(2d)
Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’
(2d)
Moderna's latest CMO steps down after barely a year
(2d)
Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech
(2d)
Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
(2d)
BioPharma Dive
Amgen gives up on its once-prized eczema drug
(2d)
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
(2d)
Politicization runs deeper than ever at FDA, risking long-term impacts
(2d)
The biopharma industry outlook on 2026: Optimism and tension
(3d)
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’
(3d)
Endpoints News
Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui’s trailblazing moment; and more
(1d)
FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug
(2d)
Bitterroot reverts to preclinical biotech in CD47 as CEO leaves
(2d)
CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild
(2d)
Ultragenyx resubmits gene therapy for rare neuro disease to FDA
(2d)
BioSpace
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate's ICE Fight
(2d)
FDA’s Multiple Myeloma Guidance Highlights Decade of Success
(2d)
TrumpRx Delayed Amid Potential Anti-Kickback Concerns
(2d)
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M
(2d)
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
(2d)
STAT News
STAT readers on shared decision-making, prostate cancer screening, and more
(1d)
Up and down the ladder: The latest comings and goings
(2d)
New rule would force PBMs to disclose drug rebates and other fees
(2d)
Newsom files a civil rights complaint against CMS’ Oz in latest feud with the Trump administration
(2d)
AstraZeneca looks to China for obesity drug candidates
(2d)
BioPharma Trend
How Digital Health Technologies are Reshaping Clinical Development
(7h)
This AI Ready Single Molecule Proteomics $1.6M Grant Targets Parkinson’s Alpha Synuclein
(3d)
Eli Lilly Strikes Up to $1.1B Gene Editing Deal with German Startup
(4d)
FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss
(4d)
This Company Claims World-First AI Models For Programmable Gene Insertion
(4d)
Drug Channels
From Cost Center to Insights Center: How Patient Support Will Go Beyond the Call in 2026
(2d)
Drug Channels News Roundup, January 2026: Cuban vs. Optum, McKesson’s Biosimilar Play, States vs. Accumulators, 340B Windfalls, and Ozempic Ads
(5d)
New Drug Launches in a Self-Pay World: Why Access Strategy Matters as Much as Innovation
(1w)
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs
(1w)
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble
(3w)
European Biotechnology Magazine
Sanofi ends 2025 on a high, but trims R&D priorities
(2d)
CDMOs dominate the headlines – and Lonza delivers a clear message of strength
(2d)
Vetter: a multi-million-euro investment for new CDMO facility boost for Saarland/Germany
(2d)
After a turbulent phase: a new milestone from Takeda for Heidelberg Pharma
(3d)
Tenpoint wins FDA approval for presbyopia eye drop and raises $235 million
(3d)
Drug Hunter
lanifibranor (IVA-337)
(2d)
2025 Novel Large Molecule FDA Drug Approvals
(3d)
ADCs With Topoisomerase I Inhibitor Payloads Are Challenging Standards of Care in Oncology
(4d)
December 2025 Patent Highlights
(5d)
Hepatotoxicity Headaches: One of the Hardest Risks to De-Risk
(6d)
Labiotech.EU
Johnson & Johnson’s pipeline strategy: What does 2026 have in store for the big pharma?
(2d)
Building a smart oncology pipeline with Cumulus Oncology
(2d)
U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals
(4d)
U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals
(4d)
Seven Italian biotechs to know about in 2026
(4d)
Bio IT World
Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline
(3d)
Follow the Money: Helicon Peptide Development, Next-Gen Obesity Metabolic Disease Therapies, Cell Stress Sensing Platform
(4d)
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
(5d)
Dealmakers Predict Banner Year as Biopharma M&A Momentum Builds
(1w)
Improved Drug Safety Needs Better Data Before AI
(1w)
GEN News
StockWatch: C-Suite Shakeup, Phase III Plans Jolt Cardiff Investors
(9h)
Intranasal Bird Flu Vaccine Protects Against Highly Pathogenic Strains in Rodents
(12h)
Gut Microbes Shape Cancer Growth and Immunity Through Asparagine Metabolism
(2d)
Complex DNA Written at Scale, Genyro Licenses Caltech’s Sidewinder
(2d)
Ex-CEO Behind Bars, 10x’s Clinical Ambitions, Pharma’s AI Gambit
(2d)
Cure Today
What MRD Testing Can Mean for Patients With Breast Cancer and Survivors
(7h)
A Patients Navigation Guide to Stage 2 Clear Cell Renal Cell Carcinoma
(11h)
Smoldering Multiple Myeloma: An Overview for Newly Diagnosed Patients
(1d)
Lung Carcinoid Tumors: Diagnosis, Staging and Treatment Options
(1d)
Key GI Cancer Advances from the 2026 ASCO Symposium
(2d)
Contract Pharma
Lilly to Build New Pennsylvania Manufacturing Facility
(2d)
Ardena Completes Divestment of Sweden Drug Substance Site to Nanologica
(2d)
Merz Therapeutics Taps Dan Staner as President, Region Europe
(2d)
Libris Innovations Taps Ramani Veranasi as CEO
(2d)
New Veeva Application Eliminates Paper, Streamlines Clinical Trial Data Flow
(3d)
Pharma Times
CERo reports encouraging early data from phase 1 trial of CER‑1236
(3d)
ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
(3d)
Argo Biopharma doses first patient in phase 2b trial of BW‑20829
(4d)
Akari files new patent and advances second ADC targeting CEACAM5
(4d)
BioMed X launches kidney disease project in partnership with the government of Barbados
(5d)
Medcity News
Premise-Crossover Merger: Inside the $2B Push for a New Employer Health Model
(11h)
Is It Time to Change the Independent Dispute Resolution Process of the No Surprises Act?
(11h)
Medication Affordability Depends on Total Price Transparency
(11h)
2026 Is the Year of the Doctor-Patient Relationship
(12h)
Clinical Trial Holds Cast Doubt on Approval Chances of Regenxbio Gene Therapy for Rare Disease
(13h)
Chemical & Engineering News
Jan. 30 Policy Watch: EPA re-ups plan to ditch animal testing for certain chemicals
(2d)
AstraZeneca signs $18.5 billion weight-loss-drug deal with Chinese firm
(2d)
Ancient Romans used human feces to make medicines
(2d)
‘ACS Nutrition Science’ publishes first issue
(2d)
US ultraprocessed food policy accelerates with bipartisan support
(2d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to January 30, 2026
(15h)
Kyowa Kirin to regain control of rocatinlimab
(1d)
Lundbeck presents new real-world data on Vyepti
(1d)
January 2026 batch of EMA/CHMP recommendations
(2d)
Strong quarter rounds off solid year for Regeneron
(2d)
Targeted Oncology
Clinical Framing and Prognostic Assessment in Progressive Small Bowel Neuroendocrine Tumors
(13h)
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
(14h)
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
(1d)
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
(1d)
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
(2d)
MedWatch
Employee representative leaves board of Novo Nordisk
(1d)
Eli Lilly plans to build a new factory in Pennsylvania for $3.5 billion
(1d)
Novo Nordisk’s director in China steps down
(2d)
Lundbeck shows strong performance again with best-selling migraine medication in new study
(2d)
Novo Nordisk nears EU approval for MASH drug
(2d)
In The Pipeline
A New LLM System for Synthesis Planning
(2d)
Rev Up The Viral Factories!
(3d)
Add Up Those Energies
(4d)
The Disastrous US Vaccine Landscape
(5d)
Microstructures All Around
(1w)
Pharmaphorum
EMA looks into 'data integrity' issue with Amgen's Tavneos
(2d)
FDA starts review of Summit's VEGFxPD-1 bispecific
(2d)
Three more biotechs price their Nasdaq IPOs
(2d)
GLP-1 drugs linked to pancreatitis, gallbladder problems
(2d)
AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal
(2d)
Drug Discovery Weekly
AZ expands China operations, agrees obesity deal with CSPC
(2d)
This week in Drug Discovery (26 – 30 January)
(2d)
European Commission approves RSV vaccine
(2d)
Gedeon Richter announces transfer of neuropsychiatry product
(2d)
TECregen appoints Dr Klaas Zuideveld as CEO
(2d)
HIT Consultant
MEDITECH Announces Passing of Founder Neil Pappalardo; Michelle O’Connor Named Interim Chair
(2d)
VA Allocates $1B for EHR Modernization as Part of Record FY26 NRM Spend
(2d)
Oracle May Cut 30k Jobs and Sell Cerner to Fund $156B OpenAI Deal
(2d)
Premise Health and Crossover Health Merge to Expand Advanced Primary Care
(2d)
Inside the $1.3B ”Smart Hospital”: How UCI Health and GW RhythmX Are Rewiring the Patient Experience
(2d)
Insights: Pink Sheet
Public Complete Responses: US FDA Revised Corcept’s Letter To Fix Clarity, Not Facts
(2d)
Accelerated Approvals Perked Up While US FDA Excelled At Being Average In 2025
(2d)
Pink Sheet Podcast: Understanding US FDA’s CNPV Application Reviews
(2d)
Kygevvi & Kayshild Among Six Products To Get EMA Nod As Tavneos Faces Data Integrity Scrutiny
(2d)
EMA Backs Sanofi’s Rezurock After Initial Rejection On Advice From External Experts
(2d)
BioXconomy
AstraZeneca makes $18.5bn bet on CSPC’s weight loss drugs
(2d)
Inside Chiesi’s rare disease partnership playbook
(2d)
Finding the opportunity in challenging times: Europe’s biotech landscape
(3d)
AbbVie strikes $100bn deal with Trump administration to boost US drug access and manufacturing
(4d)
Immuno Cure’s DNA-based HIV vaccine trial begins in China
(4d)
BioCentury
2026 Cardiovascular Catalysts: Lp(a) on the Horizon
(2d)
2026 Catalysts: Breakthrough progress in renal disease
(2d)
Eikon aims high for NASDAQ listing: Public Equity Report
(2d)
Survey results: What sponsors say is slowing cancer trials — and what’s helping
(2d)
AZ signals all-in on obesity via CSPC deal for $1.2B up front
(2d)
SCRIP
Sun On ‘Disciplined’ M&A Approach, Day 1 Launch Readiness For Semaglutide In India
(2h)
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life
(2d)
Quince Therapeutics’ Fruit Spoils As Phase III A-T Study Falls To Ground
(2d)
Amgen Returns Eczema Drug To Kyowa Kirin On Marketability Doubts
(2d)
Roche Awaits Key Readouts In 2026 – Including Its Potential Biggest Ever Drug
(2d)